Subscribe To

Price Alert Latest News Economic Calendar News

AUTL / Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 10-13, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Autolus

Therapeutics

Present

Three

Clinical

Data

Updates

American

Society

Hematology

Annual

Meeting

Stock

AUTL

Posted: Nov 3 2022, 09:31

Author Name: GlobeNewsWire

AUTL News

By Seeking Alpha
November 3, 2023

Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Re

By GlobeNewsWire
October 11, 2023

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generat

By Seeking Alpha
August 6, 2023

Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. L

By Seeking Alpha
June 30, 2023

Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket

Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position shoul

By InvestorPlace
June 14, 2023

3 Top Penny Stock Picks You Haven't Heard Of

Unless you regularly invest in or research penny stocks it's likely you aren't familiar with most companies in the space. These penny stock picks are

By Seeking Alpha
March 7, 2023

Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executiv

By GlobeNewsWire
December 12, 2022

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generat

By The Motley Fool
December 9, 2022

Why Autolus Therapeutics Stock Is Crashing Today

The biopharmaceutical company announced the pricing of a secondary stock offering.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.